LRIG and cancer prognosis

Acta Oncologica

Volumn 53, Issue 9, 2014, Pages 1135-1142

  Lindquist, David ^a   Kvarnbrink, Samuel ^a   Henriksson, Roger ^a   Hedman, Håkan ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH FACTOR; MEMBRANE PROTEIN; LRIG1 PROTEIN, HUMAN; LRIG2 PROTEIN, HUMAN; LRIG3 PROTEIN, HUMAN; MESSENGER RNA; TUMOR MARKER; TUMOR PROTEIN;

BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DRUG SENSITIVITY; GENE DOSAGE; GENE EXPRESSION; GLIOMA; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN 1 GENE; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN 2 GENE; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN 3 GENE; NASOPHARYNX CARCINOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PREDICTION; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOMA; TUMOR GENE; UTERINE CERVIX CANCER; ANIMAL; BREAST TUMOR; DOWN REGULATION; FEMALE; GENETICS; HEAD AND NECK TUMOR; LUNG TUMOR; MALE; METABOLISM; MORTALITY; MOUSE; NASOPHARYNX TUMOR; NEOPLASM; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; UPREGULATION; UTERINE CERVIX TUMOR;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; GLIOMA; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 84907197061     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.953258     Document Type: Review

References (66)

1. Krig SR, Frietze S, Simion C, Miller JK, Fry WH, Rafidi H, et al. Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ER alpha-positive breast cancer. Mol Cancer Res 2011;9: 1406-17.
2. Thompson PA, Ljuslinder I, Tsavachidis S, Brewster A, Sahin A, Hedman H, et al. Loss of LRIG1 locus increases risk of early and late relapse of stage I/II breast cancer. Cancer Res 2014;74:2928-35.
3. Lindstrom AK, Ekman K, Stendahl U, Tot T, Henriksson R, Hedman H, et al. LRIG1 and squamous epithelial uterine cervical cancer: Correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 2008;18:312-7.
4. Hedman H, Lindstrom AK, Tot T, Stendahl U, Henriksson R, Hellberg D. LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncol 2010;49:812-5.
5. Muller S, Lindquist D, Kanter L, Flores-Staino C, Henriksson R, Hedman H, et al. Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma. Int J Oncol 2013;42:247-52.
6. Sheu JJ, Lee CH, Ko JY, Tsao GS, Wu CC, Fang CY, et al. Chromosome 3p12.3-p14.2 and 3q26.2-q26.32 are genomic markers for prognosis of advanced nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2009;18: 2709-16.
7. Sheu JJ, Lee CC, Hua CH, Li CI, Lai MT, Lee SC, et al. LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling. Oncogene 2014;33:1375-84.
8. Lindquist D, Nasman A, Tarjan M, Henriksson R, Tot T, Dalianis T, et al. Expression of LRIG1 is associated with good prognosis and human papillomavirus status in oropha-ryngeal cancer. Br J Cancer 2014;110:1793-800.
9. Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H, et al. Perinuclear leucine-rich repeats and immu-noglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol 2006; 111:238-46.
10. Holmlund C, Haapasalo H, Yi W, Raheem O, Brannstrom T, Bragge H, et al. Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathol- ogy 2009;29:242-7.
11. Thomasson M, Wang B, Hammarsten P, Dahlman A, Persson JL, Josefsson A, et al. LRIG1 and the liar paradox in prostate cancer: A study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer 2011;128:2843-52.
12. Tanemura A, Nagasawa T, Inui S, Itami S. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: Immunohistochemical analysis for 38 cases. Dermatol Surg 2005;31:423-30.
13. WangY, Poulin EJ, Coffey RJ. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Br J Cancer 2013;108:1765-70.
14. Hedman H, Henriksson R. LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? Eur J Cancer 2007;43:676-82.
15. Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, Henriksson R, et al. Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 2001;284:1155-61.
16. Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, Henriksson R, et al. Characterization and tissue-specific expression of human LRIG2. Gene 2004;332:35-43.
17. Guo D, Holmlund C, Henriksson R, Hedman H. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics 2004;84:157-65.
18. Nilsson J, Starefeldt A, Henriksson R, Hedman H. LRIG1 protein in human cells and tissues. Cell Tissue Res 2003; 312:65-71.
19. Suzuki Y, Sato N, Tohyama M, Wanaka A, Takagi T. cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains. J Biol Chem 1996;271:22522-7.
20. Homma S, Shimada T, Hikake T, Yaginuma H. Expression pattern of LRR and Ig domain-containing protein (LRRIG protein) in the early mouse embryo. Gene Expr Patterns 2009;9:1-26.
21. Karlsson T, Mark EB, Henriksson R, Hedman H. Redistribution of LRIG proteins in psoriasis. J Invest Dermatol 2008; 128:1192-5.
22. Hedman H, Nilsson J, Guo D, Henriksson R. Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncol 2002;41:352-4.
23. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 2004;23: 3270-81.
24. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL, 3rd, et al. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyro-sine kinases. J Biol Chem 2004;279:47050-6.
25. Jensen KB, Watt FM. Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence. Proc Natl Acad Sci U S A 2006;103:11958-63.
26. Yang WM, Yan ZJ, Ye ZQ, Guo DS. LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87. Br J Urol Int 2006;98:898-902.
27. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway KL, 3rd, et al. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 2007;27:1934-46.
28. Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, et al. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res 2008;68:8286-94.
29. Stutz MA, Shattuck DL, Laederich MB, Carraway KL 3rd, Sweeney C. LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 2008;27:5741-52.
30. Yi W, Holmlund C, Nilsson J, Inui S, Lei T, Itami S, et al. Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1. Exp Cell Res 2011;317:504-12.
31. Lu L, Teixeira VH, Yuan Z, Graham TA, Endesfelder D, Kolluri K, et al. LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development. J Pathol 2013;229:608-20.
32. Lee JM, Kim B, Lee SB, Jeong Y, Oh YM, Song YJ, et al. Cbl-independent degradation of Met: Ways to avoid agonism of bivalent Met-targeting antibody. Oncogene 2014;33:34-43.
33. Ledda F, Bieraugel O, Fard SS, Vilar M, Paratcha G. Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci 2008;28:39-49.
34. Rondahl V, Holmlund C, Karlsson T, Wang B, Faraz M, Henriksson R, et al. Lrig2-deficient mice are protected against PDGFB-induced glioma. PLoS One 2013;8:e73635.
35. Nakamura T, Hamuro J, Takaishi M, Simmons S, Maruyama K, Zaffalon A, et al. LRIG1 inhibits STAT3-dependent inflammation to maintain corneal homeostasis. J Clin Invest 2014;124:385-97.
36. Gumienny TL, Macneil L, Zimmerman CM, Wang H, Chin L, Wrana JL, et al. Caenorhabditis elegans SMA-10/LRIG is a conserved transmembrane protein that enhances bone morphogenetic protein signaling. PLoS Genet 2010; 6:e1000963.
37. Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, Agnew C, et al. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 2007;18;26:368-81.
38. Johansson M, Oudin A, Tiemann K, Bernard A, Keunen O, Fack F, et al. The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. Neuro Oncol 2013;15:1200-11.
39. Suzuki Y, Miura H, Tanemura A, Kobayashi K, Kondoh G, Sano S, et al. Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett 2002;521: 67-71.
40. Jensen KB, Collins CA, Nascimento E, Tan DW, Frye M, Itami S, et al. Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermis. Cell Stem Cell 2009;4:427-39.
41. Wong VW, Stange DE, Page ME, Buczacki S, Wabik A, Itami S, et al. Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol 2012;14:401-8.
42. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, et al. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 2012;149:146-58.
43. Stuart HM, Roberts NA, Burgu B, Daly SB, Urquhart JE, Bhaskar S, et al. LRIG2 mutations cause urofacial syndrome. Am J Hum Genet 2013;92:259-64.
44. Wang B, Han L, Chen R, Cai M, Han F, Lei T, et al. Downregulation of LRIG2 expression by RNA interference inhibits glioblastoma cell (GL15) growth, causes cell cycle redistribution, increases cell apoptosis and enhances cell adhesion and invasion in vitro. Cancer Biol Ther 2009;8: 1018-23.
45. Abraira VE, Del Rio T, Tucker AF, Slonimsky J, Keirnes HL, Goodrich LV. Cross-repressive interactions between Lrig3 and netrin 1 shape the architecture of the inner ear. Development 2008;135:4091-9.
46. Abraira VE, Satoh T, Fekete DM, Goodrich LV. Vertebrate Lrig3-ErbB interactions occur in vitro but are unlikely to play a role in Lrig3-dependent inner ear morphogenesis. PLoS One 2010;5:e8981.
47. Zhao H, Tanegashima K, Ro H, Dawid IB. Lrig3 regulates neural crest formation in Xenopus by modulating Fgf and Wnt signaling pathways. Development 2008;135: 1283-93.
48. Rafidi H, Mercado F 3rd, Astudillo M, Fry WH, Saldana M, Carraway KL 3rd, et al. Leucine-rich repeat and immu-noglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3). J Biol Chem 2013;288: 21593-605.
49. He XY, Liu XJ, Chen X, Bian LG, Zhao WG, Shen JK, et al. Gambogic acid induces EGFR degradation and Akt/mTORC1 inhibition through AMPK dependent-LRIG1 upregulation in cultured U87 glioma cells. Biochem Biophys Res Commun 2013;435:397-402.
50. Boelens MC, van den Berg A, Fehrmann RS, Geerlings M, de Jong WK, te Meerman GJ, et al. Current smoking-specific gene expression signature in normal bronchial epithelium is enhanced in squamous cell lung cancer. J Pathol 2009; 218:182-91.
51. Wang D, Rendon A, Ouwehand W, Wernisch L. Transcription factor co-localization patterns affect human cell type-specific gene expression. BMC Genomics 2012;13:263.
52. Nagata M, Nakamura T, Sotozono C, Inatomi T, Yokoi N, Kinoshita S. LRIG1 as a potential novel marker for neoplas-tic transformation in ocular surface squamous neoplasia. PLoS One 2014;9:e93164.
53. Thomasson M, Hedman H, Ljungberg B, Henriksson R. Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma. BMC Res Notes 2012;5:216.
54. Hanlon K, Rudin CE, Harries LW. Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lym- phocytic leukemia (CLL). PLoS One 2009;4:e7169.
55. Jensen KB, Jones J, Watt FM. A stem cell gene expression profile of human squamous cell carcinomas. Cancer Lett 2008;272:23-31.
56. Ye F, Gao Q, Xu T, Zeng L, Ou Y, Mao F, et al. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity. J Neurooncol 2009;94:183-94.
57. Ljuslinder I, Malmer B, Golovleva I, Thomasson M, Grankvist K, Hockenstrom T, et al. Increased copy number at 3p14 in breast cancer. Breast Cancer Res 2005;7:R719-27.
58. Ljuslinder I, Golovleva I, Henriksson R, Grankvist K, Malmer B, Hedman H. Co-incidental increase in gene copy number of ERBB2 and LRIG1 in breast cancer. Breast Cancer Res 2009;11:403.
59. Ljuslinder I, Golovleva I, Palmqvist R, Oberg A, Stenling R, Jonsson Y, et al. LRIG1 expression in colorectal cancer. Acta Oncol 2007;46:1118-22.
60. Thomasson M, Hedman H, Guo D, Ljungberg B, Henriksson R. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: A quantitative RT-PCR and immu-nohistochemical analysis. Br J Cancer 2003;89:1285-9.
61. Wu X, Hedman H, Bergqvist M, Bergstrom S, Henriksson R, Gullbo J, et al. Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity. Acta Oncol 2012;51:69-76.
62. Ghasimi S, Haapasalo H, Eray M, Korhonen K, Brannstrom T, Hedman H, et al. Immunohistochemical analysis of LRIG proteins in meningiomas: Correlation between estrogen receptor status and LRIG expression. J Neurooncol 2012;108:435-41.
63. Rouam S, Moreau T, Broet P. Identifying common prognostic factors in genomic cancer studies: A novel index for censored outcomes. BMC Bioinformatics 2010;11:150.
64. Li F, Yang W, Guo D, Hu Z, Xu H, Ye Z. LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway. Oncol Rep 2011;25:1629-37.
65. Qi XC, Xie DJ, Yan QF, Wang YR, Zhu YX, Qian C, et al. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2. Biochem Biophys Res Commun 2013;437:565-72.
66. Bai L, McEachern D,Yang CY, Lu J, Sun H, Wang S. LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFa expression and receptor tyrosine kinase signaling. Cancer Res 2012;72:1229-38.